open access

Vol 65, No 6 (2015)
Guidelines / Expert consensus
Published online: 2016-02-05
Get Citation

Recommendations for diagnosis and therapy of cutaneous melanoma

Piotr Rutkowski, Piotr J. Wysocki, Anna Nasierowska-Guttmejer, Jacek Fijuth, Ewa Kalinka-Warzocha, Tomasz Świtaj, Arkadiusz Jeziorski, Milena Szacht, Wojciech Zegarski, Wojciech M. Wysocki, Lidia Rudnicka, Witold Owczarek, Maciej Krzakowski
DOI: 10.5603/NJO.2015.0106
·
Nowotwory. Journal of Oncology 2015;65(6):501-516.

open access

Vol 65, No 6 (2015)
Recommendations
Published online: 2016-02-05

Abstract

Dermoscopy is currently the standard method for clinical differential diagnosis of cutaneous melanoma and for qualifying a lesion for excision biopsy. Full thickness excision biopsy of suspicious melanomatous skin lesions is likely to be diagnosed as early melanomaand is crucial in establishing diagnosis and defining prognostic factors. Early diagnosis and surgical removal of cutaneous melanoma not only improves prognosis, but it is also associated with approximately 90% likelihood of cure. Next steps in the therapeutic management of cutaneous melanoma following excision biopsy are radical scar excision with adequate margins and sentinel lymph node biopsy. Radical lymph node dissection is recommended in case of regional lymph node metastases. High-risk patients (lymph node involvement and/or ulcerated primary lesion) should be advised to participate in prospective clinical trials on adjuvant therapy. Melanoma patients with distant metastases are still characterised by poor outcomes. In patients with metastatic disease testing for the presence of BRAF gene mutation is mandatory Patients with metastatic disease should be considered for participation in clinical trials. Long-term survival is confined to selected group of patients undergoing resection of isolated metastatic lesions. In systemic (mainly first-line) therapy of patients with BRAF V600 mutation BRAF inhibitor, vemurafenib or dabrafenib (preferentially in combination with MEK inhibitor) may be employed and independently of mutational status immunotherapy with anti-PD-1 antibodies (nivolumab or pembrolizumab), and eventually ipilimumab (anti-CTLA4 antibody) may be used.

Abstract

Dermoscopy is currently the standard method for clinical differential diagnosis of cutaneous melanoma and for qualifying a lesion for excision biopsy. Full thickness excision biopsy of suspicious melanomatous skin lesions is likely to be diagnosed as early melanomaand is crucial in establishing diagnosis and defining prognostic factors. Early diagnosis and surgical removal of cutaneous melanoma not only improves prognosis, but it is also associated with approximately 90% likelihood of cure. Next steps in the therapeutic management of cutaneous melanoma following excision biopsy are radical scar excision with adequate margins and sentinel lymph node biopsy. Radical lymph node dissection is recommended in case of regional lymph node metastases. High-risk patients (lymph node involvement and/or ulcerated primary lesion) should be advised to participate in prospective clinical trials on adjuvant therapy. Melanoma patients with distant metastases are still characterised by poor outcomes. In patients with metastatic disease testing for the presence of BRAF gene mutation is mandatory Patients with metastatic disease should be considered for participation in clinical trials. Long-term survival is confined to selected group of patients undergoing resection of isolated metastatic lesions. In systemic (mainly first-line) therapy of patients with BRAF V600 mutation BRAF inhibitor, vemurafenib or dabrafenib (preferentially in combination with MEK inhibitor) may be employed and independently of mutational status immunotherapy with anti-PD-1 antibodies (nivolumab or pembrolizumab), and eventually ipilimumab (anti-CTLA4 antibody) may be used.

Get Citation
About this article
Title

Recommendations for diagnosis and therapy of cutaneous melanoma

Journal

Nowotwory. Journal of Oncology

Issue

Vol 65, No 6 (2015)

Article type

Guidelines / Expert consensus

Pages

501-516

Published online

2016-02-05

DOI

10.5603/NJO.2015.0106

Bibliographic record

Nowotwory. Journal of Oncology 2015;65(6):501-516.

Authors

Piotr Rutkowski
Piotr J. Wysocki
Anna Nasierowska-Guttmejer
Jacek Fijuth
Ewa Kalinka-Warzocha
Tomasz Świtaj
Arkadiusz Jeziorski
Milena Szacht
Wojciech Zegarski
Wojciech M. Wysocki
Lidia Rudnicka
Witold Owczarek
Maciej Krzakowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl